Entrada Therapeutics Stock Alpha and Beta Analysis
| TRDA Stock | USD 13.44 0.81 6.41% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Entrada Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Entrada Therapeutics over a specified time horizon. Remember, high Entrada Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Entrada Therapeutics' market risk premium analysis include:
Beta 0.66 | Alpha (0.54) | Risk 3.52 | Sharpe Ratio (0.11) | Expected Return (0.40) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Entrada |
Entrada Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Entrada Therapeutics market risk premium is the additional return an investor will receive from holding Entrada Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Entrada Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Entrada Therapeutics' performance over market.| α | -0.54 | β | 0.66 |
Entrada Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Entrada Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Entrada Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Entrada Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Entrada Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Entrada Therapeutics shares will generate the highest return on investment. By understating and applying Entrada Therapeutics stock market price indicators, traders can identify Entrada Therapeutics position entry and exit signals to maximize returns.
Entrada Therapeutics Return and Market Media
The median price of Entrada Therapeutics for the period between Tue, Nov 19, 2024 and Mon, Feb 17, 2025 is 17.46 with a coefficient of variation of 17.78. The daily time series for the period is distributed with a sample standard deviation of 2.94, arithmetic mean of 16.54, and mean deviation of 2.64. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 100 shares by Natarajan Sethuraman of Entrada Therapeutics at 20.0 subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 4088 shares by Natarajan Sethuraman of Entrada Therapeutics at 20.2626 subject to Rule 16b-3 | 12/02/2024 |
3 | Insider Sell Alert Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc | 12/04/2024 |
4 | Is Entrada Therapeutics, Inc.s Recent Stock Performance Tethered To Its Strong Fundamentals | 12/09/2024 |
5 | Disposition of 22935 shares by Mpm Bioventures 2014, L.p. of Entrada Therapeutics at 20.77 subject to Rule 16b-3 | 12/10/2024 |
6 | Recent Price Trend in Entrada Therapeutics is Your Friend, Heres Why | 12/11/2024 |
7 | Best Momentum Stocks to Buy for December 30th - Yahoo Finance | 12/30/2024 |
8 | Entrada Therapeutics Trading Down 7.6 percent - Heres Why - MarketBeat | 01/10/2025 |
9 | Entrada Therapeutics Corporate Presentation - Marketscreener.com | 01/15/2025 |
10 | Azenta Announces the Election of Dipal Doshi to its Board of Directors -January 30, 2025 at 0406 pm EST - Marketscreener.com | 01/30/2025 |
11 | BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc | 02/04/2025 |
12 | Entrada Therapeutics Buy Rating Reiterated at HC Wainwright - MarketBeat | 02/07/2025 |
13 | JANUS HENDERSON GROUP PLCs Strategic Acquisition in Entrada Therapeutics Inc | 02/14/2025 |
About Entrada Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Entrada or other stocks. Alpha measures the amount that position in Entrada Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Graham Number | 5.2 | 8.22 | Receivables Turnover | 19.75 | 17.56 |
Entrada Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Entrada Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entrada Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Entrada Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Entrada Therapeutics. Please utilize our Beneish M Score to check the likelihood of Entrada Therapeutics' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Entrada Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Entrada Therapeutics Backtesting, Entrada Therapeutics Valuation, Entrada Therapeutics Correlation, Entrada Therapeutics Hype Analysis, Entrada Therapeutics Volatility, Entrada Therapeutics History and analyze Entrada Therapeutics Performance. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Entrada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.